Table 4. Multivariate analysis for OS and PFS.
| PFSa | OSb | |||
|---|---|---|---|---|
| Characteristic | HR (95% CI) | p value | HR (95% CI) | p value |
| Bevacizumab | ||||
| No | 1 | 0.084 | 1 | 0.401 |
| Yes | 0.54 (0.26–1.09) | 0.70 (0.30–1.61) | ||
| Surgery | ||||
| Primary cytoreduction | - | - | 1 | 0.088 |
| Interval cytoreduction | - | 2.04 (0.90–4.65) | ||
| CCNE1 overexpression | ||||
| No | 1 | 0.026 | 1 | 0.035 |
| Yes | 2.25 (1.10–4.60) | (1.07–5.45) | ||
a
49 patients with complete data included in the multivariate analysis, 38 events
b
46 patients with complete data included in the multivariate analysis, 36 events
PFS, Progression free survival; OS, Overall survival